(Quellen können Bezahlschranken aufweisen)
Abbas, Zulfiqarali G. (2017) Managing the diabetic foot in resource-poor settings: challenges and solutions. In: Chronic Wound Care Management and Research; Vol. 4, p 135-142
Gettleman, Jeffrey (2018) In Kenya and Across Africa, an Unexpected Epidemic: Obesity. In: New York Times, 27. Jan., https://www.nytimes.com/2018/01/.../kenya-obesity-diabetes.html [Zugriff am 11.2.2018]
Guell, Cornelia & Unwin, Nigel (2015) Barriers to diabetic foot care in a developing country with a high incidence of diabetes related amputations: an exploratory qualitative interview study. In: BMC Health Services Research; Vol. 15, 377
Hofman, K.J. et al. (2014) Preventing diabetic blindness: A priority for South Africa. In: South African Medical Journal; Vol. 104, No. 10, p 661-2
Hu, Frank B. (2011) Globalization of Diabetes. The role of diet, lifestlye, and genes. In: Diabetes Care; Vol. 34, p 1249-1257
IDF (2017) IDF Diabetes Atlas 2017. https://www.idf.org/e-library/epidemiology-research/diabetes-atlas/134-idf-diabetes-atlas-8th-edition.html. [Zugriff am 15.12.2017]
Nanditha A. et al. (2016): Diabetes in Asia and the Pacific: Implications for the Global Epidemic. In: Diabetes Care; Vol. 39, p 472-485
THE LANCET (2018) The Lancet Taskforce on NCDs and economics. https://www.thelancet.com/series/Taskforce-NCDs-and-economics [Zugriff am 24.08.2018]
Utz, Bettina et al. (2016) Detection and Management of Diabetes during Pregnancy in Low Resource Settings: Insights into Past and Present Clinical Practices. In: Journal of Diabetes Research; Vol. 2016, 14 pages
Hieroglyphen: Pixabay / Trapuzarra / CC0 Creative Commons
Übergewichtiger Mann: Wikimedia / Juanedc / Creative Commons Attribution 2.0 Generic
Favela in Rio de Janeiro: Shutterstock / Donatas Dabravolskas / Standard Shutterstocklizenz
Getränkeflaschen in Supermarkt: Shutterstock / Anton _Ivanov / Standard Shutterstocklizenz
Kind in Behandlung: Insulininjektion: Foto Quelle: Shutterstock / Riccardo Mayer / Shutterstock Standardlizenz
Bailey, Sarah Lou and Grant, Paul (2011) ‘The tubercular diabetic’: the impact of diabetes mellitus on tuberculosis and its threat to global tuberculosis control. In: Clinical Practice; Vol. 11, No. 4, p 344-7
Bowe, Benjamin et al. (2018) The 2016 global and national burden of diabetes mellitus attributable to PM2·5 air pollution. In: Lancet Planet Health; Vol. 2, p 301-12
CDC (2018) Smoking and Diabetes. https://www.cdc.gov/tobacco/campaign/tips/diseases/diabetes.html [Zugriff am 24.08.2018]
Kalra, Sanjay et al. (2011) Understanding diabetes in patients with HIV/AIDS. In: Diabetology & Metabolic Syndrome; Vol. 3, No. 2, 7 pages
Li, Yanping et al. (2011) Exposure to the Chinese Famine in Early Life and the Risk of Metabolic Syndrome in Adulthood. In: Diabetes Care; Vol. 34, p 1014-8.
McCombie, Louise et al. (2017) Beating type 2 diabetes into remission. In: BMJ; Vol. 358, 6 pages
Pecoits-Filho, Roberto et al. (2016) Interactions between kidney disease and diabetes: dangerous liaisons. In: Diabetology & Metabolic Syndrome; Vol. 8, No. 50, 21 pages
Remais, Justin V. et al. (2013) Convergence of non-communicable and infectious diseases in low- and middle-income countries. In: International Journal of Epidemiology; Vo. 42, p 221-7
Schiavone et al. (2016) Gestational diabetes: An overview with attention for developing countries. In: Endocrine Regulations; Vol. 50, No. 2, p 62-71
The Union & WDF (2014) Collaborative framework for care and control of tuberculosis and diabetes. http://apps.who.int/iris/bitstream/handle/10665/44698/9789241502252_eng.pdf?sequence=1 [Zugriff am 24.08.2018]
Rauchender Schornstein: Pixabay / Chris_LeBoutillier / CC0 Creative Commons
Schwangere am Strand: Wikimedia / Graham Crumb / Creative Commons Attribution-Share Alike 3.0 Unported
Mycobacterium tuberculosis: Wikimedia / NIAID / Public Domain
ART-Tabletten: Wikimedia / NIAID / Creative Commons Attribution 2.0 Generic
Anopheles stephensi: Wikimedia / Jim Gathany / Public Domain
Grafik Insulin und Glucon: Shutterstock / Designua / Shutterstock Standardlizenz
Grafik Insulinresistenz: Shutterstock / arka38 / Shutterstock Standardlizenz
Grafik Auge: Shutterstock / Alila Medical Media / Shutterstock Standardlizenz
Bein nach Amputation: Shutterstock / ChooChin / Shutterstock Standardlizenz
Atun, Rifat et al. (2017) Diabetes in sub-Saharan Africa: from clinical care to health policy. In: The Lancet Diabetes & Endocrinology; Vol. 5, No. 8, 46 pages
Beran, David et al. (2016) Constraints and challenges in access to insulin: a global perspective. In: Lancet Diabetes & Endocrinology; Vol. 4, No. 3, p 11 pages
Beran, David & Yudkin, John S. (2010) Looking beyond the issue of access to insulin: What is needed for proper diabetes care in resource poor settings. In: Diabetes Research and Clinical Practice; Vol. 88, p 217-21
Esterson, Yonah B. et al. (2014) A systematic review of innovative diabetes care models in low-and middle-income countries (LMICs). In: Journal of Health Care for the Poor and Underserve; Vol. 25, No. 1, p 72-93
HAI (2017) Access to insulin: Current challenges and constraints. Update March 2017. http://haiweb.org/wp-content/uploads/2017/03/Issues_Paper_2017.pdf [Zugriff am 24.08.2018]
HAI (2017) Insulin users` perspective profile. http://haiweb.org/wp-content/uploads/2017/05/Insulin-Users-Perspective-Profile.pdf [Zugriff am 24.08.2018]
Harris, Anthony D. (2016) Addressing diabetes mellitus as part of the strategy for ending TB. In: Transactions of the Royal Society of Tropical Medicine and Hygiene; Vol. 110, p 173-9
Hill, Andrew M. et al (2018): Estimated costs of production and potential prices for the WHO Essential Medicines List. In: BMJ Global Health, Vol. 3, 7 pages
Kalra, Sanjay et al. (2017) Malaria and diabetes. In: Recent Advances in Endocrinology; Vol. 67, No. 5, p 810-3
Lipska, Kasia J. et al. (2018) Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits or Hospital Admissions and With Glycemic Control in Patients With Type 2 Diabetes. In: JAMA Original Investigation; Vol. 320, No. 1, p 53-62
Peer, Nasheeta (2015) The converging burdens of infectious and non-communicable diseases in rural-to-urban migrant Sub-Saharan African populations: a focus on HIV/AIDS, tuberculosis and cardio-metabolic diseases. In: Tropical Diseases, Travel Medicine and Vaccines; Vol. 1, No. 6, 8 pages
Tung, Elizabeth L. et al. (2018) Glycemic Control in Nonpregnant Adults With Type 2 Diabetes. In: JAMA Clinical Guidelines Synopsis; Vol. 319, No. 23, p 2430-1
WHO (2008) Direct costs and Availability of Diabetes Medicines in Low-income and Middle-income Countries. http://apps.who.int/medicinedocs/documents/s18387en/s18387en.pdf [Zugriff am 24.08.2018]
Yudkin, John S. (2012) Industry is a barrier to diabetes care in poor countries. In: BMJ; Vol. 344, p 36
Blutzucker-Messung: Wikimedia / Biswarup Ganguly / Creative Commons Attribution 3.0 Unported
Grafik Glucagon: T1International / Nutzungserlaubnis erteilt
Health Worker mit Handy: Wikimedia / Health Builders / Creative Commons Attribution-Share Alike 4.0. International
Grafik Kosten abseits von Insulin: HAI / Nutzungserlaubnis erteilt
Teststreifen: Shutterstock / Dr Arindam / Shutterstock Standardlizenz
Empowerment Werkzeuge: Shutterstock / EtiAmmos / Shutterstock Standardlizenz
American Diabetes Association (2017): 8. Pharmacologic Approaches to Glycemic Treatment. Diabetes Care 40: S64-s74
American Diabetes Association (2018): 13. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes-2018. Diabetes Care 41: S137-S143
Bailey CJ (2017): Metformin: historical overview. Diabetologia 60: 1566-1576
Black C, Donnelly P, McIntyre L, Royle P, Shepherd Jonathan J, Thomas S (2007): Meglitinide analogues for type 2 diabetes mellitus. The Cochrane Database of Systematic Reviews 2:CD004654
Boussageon R, Supper I, Bejan-Angoulvant T, et al. (2012) Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med 9: e1001204
Brown J, Grzeskowiak L, Williamson K, Downie MR, Crowther CA (2017): Insulin for the treatment of women with gestational diabetes. The Cochrane Database of Systematic Reviews 11: CD012037
Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) (2014): Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes – Langfassung, 1. Auflage. Version 4. Available from: www.dm-therapie.versorgungsleitlinien.de [Zugriff am 10.04.2018].
Chamberlain JJ, Herman WH, Leal S, et al. (2017): Pharmacologic Therapy for Type 2 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med 166: 572-578
Deutsche Gesellschaft für Gynäkologie und Geburtshilfe, Deutsche Diabetes Gesellschaft (2018): S3-Leitlinie Gestationsdiabetes mellitus (GDM), Diagnostik, Therapie und Nachsorge. 2. Auflage. Available from http://www.awmf.org/leitlinien/detail/ll/057-008.html, [Zugriff am 06.05.2018]
Dormandy JA, Charbonnel B, Eckland DJ, et al. (2005): Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366(9493):1279-1289.
Egan AG, Blind E, Dunder K, et al. (2014): Pancreatic safety of incretin-based drugs--FDA and EMA assessment. NEJM 370: 794-797
European Medicines Agency (2016): Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function. EMA/603690/2016. Available from http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2016/10/WC500214248.pdf, [Zugriff am 12.04.2018]
Freichel M, Mengel K (2017): Antidiabetika. In: Schwabe U, Paffrath D, Ludwig WD, Klauber J (Hrsg.): Arzneiverordnungs-Report 2017. Springer Berlin Heidelberg
Fullerton B, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A (2014): Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. The Cochrane Database of Systematic Reviews:CD009122
Fullerton B, Siebenhofer A, Jeitler K, et al. (2016): Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus. The Cochrane Database of Systematic Reviews:CD012161
Gigerenzer G, Kolpatzik K. (2017): How new fact boxes are explaining medical risk to millions. BMJ 357: j2460
Green JB, Bethel MA, Armstrong PW, et al. (2015): Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. NEJM 373: 232-242
Gururaj Setty S, Crasto W, Jarvis J, Khunti K, Davies MJ (2016): New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. Postgrad Med J 92: 152-164
Hemmingsen B, Schroll JB, Wetterslev J, et al. (2014): Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis. CMAJ Open 2: E162-175
Holman RR, Bethel MA, Mentz RJ, et al. (2017): Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. NEJM 377: 1228-1239
Holman RR, Coleman RL, Chan JCN, et al. (2017): Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 5: 877-886
Home PD, Pocock SJ, Beck-Nielsen H, et al. (2009): Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373(9681):2125-2135
Horvath K, Koch K, Jeitler K, et al. (2010): Effects of treatment in women with gestational diabetes mellitus: systematic review and meta-analysis. BMJ 340: c1395
Horvath K, Jeitler K, Berghold A, et al. (2007): Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. The Cochrane Database of Systematic Reviews: CD005613
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (2018): Dapagliflozin (Diabetes mellitus Typ 2) – Nutzenbewertung gemäß § 35a SGB V (neue wissenschaftliche Erkenntnisse). Dossierbewertung A17-65. Available from https://www.iqwig.de; Zugriff am 15.04.2018
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (2017): Saxagliptin/Metformin (Diabetes mellitus Typ 2) – Nutzenbewertung gemäß § 35a SGB V. Dossierbewertung A17-33. Available from https://www.iqwig.de; Zugriff am 15.04.2018
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (2016): Empagliflozin – Nutzenbewertung gemäß § 35a SGB V. Dossierbewertung A16-12. Available from https://www.iqwig.de; Zugriff am 15.04.2018
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (2016) Sitagliptin (Diabetes mellitus Typ 2) – Nutzenbewertung gemäß § 35a SGB V. Dossierbewertung A16-44. Available from https://www.iqwig.de; Zugriff am 15.04.2018
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (2009): Glinide zur Behandlung des Diabetes mellitus Typ 2 (A05-05C: Abschlussbericht). Available from http://www.iqwig.de/, Zugriff am 14.04.2018
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (2009): Langwirksame Insulinanaloga zur Behandlung des Diabetes mellitus Typ 2. Abschlussbericht A05-03. Available from http://www.iqwig.de/, Zugriff am 06.05.2018
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (2009): Glitazone zur Behandlung des Diabetes mellitus Typ 2 (A05-05A: Abschlussbericht). Available from http://www.iqwig.de/, Zugriff am 11.04.2018
Inzucchi SE, Bergenstal RM, Buse JB, et al. (2015): Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38: 140-149
Marso SP, Daniels GH, Brown-Frandsen K, et al. (2016): Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. NEJM 375: 311-322
Maruthur NM, Tseng E, Hutfless S, et al. (2016): Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. Ann Intern Med 164: 740-751
Nathan DM, Genuth S, Lachin J, et al. (1993): The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. NEJM 329: 977-986
National Institute for Health and Care Excellence (NICE) (2015): Type 2 diabetes in adults: managementype 2 diabetes in adults: management. NICE guideline. Available from www.nice.org.uk/guidance/ng28 [Zugriff am 10.04.2018]
Nissen SE, Wolski K (2010): Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 170(14): 1191-1201
Nissen SE, Wolski K (2007): Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. NEJM 356(24):2457-2471.
Qaseem A, Barry MJ, Humphrey LL, Forciea MA (2017): Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update From the American College of Physicians. Ann Intern Med 166: 279-290
Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D (2005): Metformin monotherapy for type 2 diabetes mellitus. The Cochrane Database of Systematic Reviews 3:CD002966.
Salpeter SR, Greyber E, Pasternak GA, Salpeter EE (2010): Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. The Cochrane Database of Systematic Reviews 4:CD002967
Scirica BM, Bhatt DL, Braunwald E, et al. (2013): Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. NEJM 369: 1317-1326
U. K. Prospective Diabetes Study Group (1998): Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352(9131):854-865
U. K. Prospective Diabetes Study Group (1998): Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352(9131):837-853
U.S. Food and Drug Administration (2016): Metformin-containing Drugs: Drug Safety Communication - Revised Warnings for Certain Patients With Reduced Kidney Function. Available from https://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm494829.htm [Zugriff am 12.04.2018]
Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, De Grauw WJ (2006): Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. The Cochrane Database of Systematic Reviews 4:CD005061
Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, Van Weel C (2005): Alpha-glucosidase inhibitors for type 2 diabetes mellitus. The Cochrane Database of Systematic Reviews 2:CD003639
Vella S, Buetow L, Royle P, Livingstone S, Colhoun HM, Petrie JR (2010): The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia 53: 809-820
White WB, Cannon CP, Heller SR, et al. (2013): Alogliptin after acute coronary syndrome in patients with type 2 diabetes. NEJM 369: 1327-1335
World Health Organisation (2017): WHO Model Lists of Essential Medicines. Available from http://www.who.int/medicines/publications/essentialmedicines/en [Zugriff am 10.04.2018]
Zhu ZN, Jiang YF, Ding T (2014): Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. Bone 68: 115-123
Zinman B, Wanner C, Lachin JM, et al. (2015): Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. NEJM 373: 2117-2128
Al-Lawati, Jawad A. (2017) Diabetes Mellitus: A Local and Global Public Health Emergency! In: Oman Medical Journal; Vol. 32, No. 3, p 177-9
Bollyky, Thomas J. et al. (2017) Lower-Income Countries That Face The Most Rapid Shift In Noncommunicable Disease Burden Are Also The Least Prepared. In: Health Affairs; Vol. 36, No. 11, p 1866-1875
Chokshi, Niraj (2016) Diabetes was once a problem of the rich. Now it belongs to the poor. In: Washington Post, 7. April, https://www.washingtonpost.com/news/to-your-health/wp/2016/04/06/diabetes-was-once-a-problem-of-the-rich-now-it-belongs-to-the-poor/?noredirect=on&utm_term=.ce1a0b34c749 [Zugriff am 31.08.2018]
Drope, Jeffrey & Schluger, Neil W. (2018) The Tobacco Atlas. Sixth Edition. https://tobaccoatlas.org/wp-content/uploads/2018/03/TobaccoAtlas_6thEdition_LoRes_Rev0318.pdf [Zugriff am 24.08.2018]
[The] Guardian (2015) The global south has free trade to thank for its obesity and diabetes epidemic. https://www.theguardian.com/commentisfree/2015/apr/06/global-south-has-free-trade-to-thank-obesity-diabetes-epidemic [Zugriff am 15.02.2018]
Jacobs, A. (2018) In sweeping war on obesity Chile slays Tony the Tiger. In: New York Times, 7. Feb. https://www.nytimes.com/2018/02/07/health/obesity-chile-sugar-regulations.html [Zugriff 09.03.2018]
Jacobs A., Richtel M. (2017) How Big Business Got Brazil Hooked on Junk Food. New York Times, 16. Sept www.nytimes.com/interactive/2017/09/16/health/brazil-obesity-nestle.html [Zugriff 02.03.2018]
[THE] LANCET (2017) Sweet success: will sugar taxes improve health? In: The Lancet Diabetes & Endocrinology; Vol., 5, p 235
Nuche-Berenguer, Bernardo & Kupfer, Linda E. (2018) Readiness of Sub-Saharan Africa Healthcare Systems for the New Pandemic, Diabetes: A Systematic Review. In: Journal of Diabetes Research; Vol. 2018, 12 pages
Pérez-Escamilla, R. et al. (2017) Prevention of childhood obesity and food policies in Latin America: from research to practice. In: Obesity Reviews; Vol. 18, p 28-38
Roache, Sarah A. & Gostin, Lawrence O. (2017) The Untapped Power of Soda Taxes: Incentivizing Consumers, Generating Revenue, and Altering Corporate Behavior. In: International Journal of Health Policy and Management; Vol. 6, No. 9, p. 489 – 493
Snowdon, W. & Thow, A.M. (2013) Trade policy and obesity prevention: challenges and innovation in the Pacific Islands. In: Obesity Reviews; Vol. 14, 150-8
Frau mit Kindern: Pixabay / etinosa_yvonne / CC0 Creative Commons
Fisch Tonga: Wikimedia / Hhardman3112 / Creative Commons Attribution-Share Alike 4.0 International
Menschen auf der Straße: Wikimedia / nati_fg / Creative Commons Attribution 2.0 Generic
Getränkflaschen: Pixabay / igorovsyannykov / CC0 Creative Commons
Hütten Malawi: Pixabay / Graham-H / CC0 Creative Commons
Füße schlafende Person: Pixabay / NinaMarie / CC0 Creative Commons
Karte Nigeria: Shutterstock / Peter Hermes Furian / Shutterstock Standardlizenz
Karte Ozeanien: Shutterstock / Pjasha / Shutterstock Standardlizenz
Karte Libanon: Shutterstock / Peter Hermes Furian / Shutterstock Standardlizenz
Portrait Dr. N. Albache: Hôtel-Dieu du Creusot / Nutzungserlaubnis erteilt
Rauchende Männer: Shutterstock / Oxana Mamlina / Shutterstock Standardlizenz
Karte Chile: Shutterstock / Peter Hermes Furian / Shutterstock Standardlizenz
Karte Malawi: Shutterstock / Peter Hermes Furian / Shutterstock Standardlizenz
Alafoé, Halimatou et al. (2017) Community Health Workers in Diabetes Prevention and Management in Developing Countries. In: Annals of Global Health, Vol. 83, No. 3-4, p 661-675
Bull World Health Organ (2016): The mysteries of type 2 diabetes in developing countries. In: Bulletin of the World Health Organization. http://dx.doi.org/10.2471/BLT.16.030416 [Zugriff am 5.2.2018], S. 242
Dandekar, Vikas (2016) India rejects compulsory license application of Lee Pharma against AstraZeneca’s Saxagliptin. 21.1.2016. https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/india-rejects-compulsory-license-application-of-lee-pharma-against-astrazenecas-saxagliptin/articleshow/50652935.cms [Zugriff am 25.10.2018]
Freedhoff, Yoni & Hébert, Paul C. (2011) Partnerships between health organizations and the food industry risk derailing public health nutrition. In: Canadian Medical Association Journal, Vol. 183, No. 3, p 291-2
Horton, Richard (2017) NCDs - why are we failing? In: THE LANCET, Vol. 390, p 346
Jacobs A., Richtel M. (2017) She Took On Colombia’s Soda Industry. Then She Was Silenced. 13.11.2017. https://www.nytimes.com/2017/11/13/health/colombia-soda-tax-obesity.html [Zugriff am 11.04.2018]
Johnson, Carolyn Y. (2016) This 90-year-old fight over insulin royalties reveals just how much has changed in medicine. 1.11.2016. https://www.washingtonpost.com/news/wonk/wp/2016/11/01/this-90-year-old-fight-over-insulin-royalties-reveals-just-how-much-has-changed-in-medicine/?noredirect=on&utm_term=.2d935aab7bb5 [Zugriff am 25.10.2018]
Lopez, Oscar & Jacobs, Andrew (2018) In Town With Little Water, Coca-Cola Is Everywhere. So Is Diabetes. In: New York Times. 14.7.2018. https://www.nytimes.com/2018/07/14/world/americas/mexico-coca-cola-diabetes.html [Zugriff am 25.10.2018]
Mbeh, George N. et al. (2010) Traditional healers and diabetes: results from a pilot project to train traditional healers to provide health education and appropriate health care practices for diabetes patients in Cameroon. In: Global Health Promotion, June 2010, p 17-26
Sobry, Agnes et al. (2014) Caseload, management and treatment outcomes of patients with hypertension and/or diabetes mellitus in a primary health care programme in an informal setting. In: Tropical Medicine and International Health, Vol. 19, No. 1, p 47-57
WHO (2018) Saving limbs from amputation. 25.5.2018. http://www.who.int/news-room/feature-stories/detail/saving-limbs-from-amputation [Zugriff am 25.10.2018]
WHO (2002) Innovative care for chronic conditions: building blocks for action: global report. http://www.who.int/chp/knowledge/publications/icccglobalreport.pdf?ua=1 [Zugriff am 25.10.2018]
Untersuchung: Wikimedia / Olivier Hébrard / Creative Commons Attribution-Share Alike 4.0 International
Diskussionsgruppe: HAI / Nutzungserlaubnis erteilt
Gruppenfoto: AYUDA / Nutzungserlaubnis erteilt
.jpg){kind=link}